NEW YORK, January 10, 2017 /PRNewswire/ --
Companies in the Medical Instruments and Supplies space primarily research, develop, and produce non-electronic medical, surgical, dental and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps and medical thermometers. Today, Stock-Callers.com has issued research reports on the following Medical Instruments and Supplies stock: Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Co. (NYSE: BDX), Antares Pharma Inc. (NASDAQ: ATRS), and TransEnterix Inc. (NYSE MKT: TRXC). Download the free research reports on these stocks today:
Irvine, California headquartered Endologix Inc.'s shares soared 5.43%, finishing Monday's trading session at $6.02. A total volume of 1.89 million shares was traded. Since the start of this year, the stock has advanced 5.24%. The Company's shares are trading below their 50-day moving average by 22.20%. Moreover, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have a Relative Strength Index (RSI) of 41.97.
On December 29th, 2016, Endologix provided an update on the previously announced temporary hold on shipments of its AFX® and AFX2® Endovascular AAA Systems. Based upon positive testing results, the Company has removed the temporary hold on all sizes of the AFX Endovascular AAA System and some sizes of the AFX2 Endovascular AAA System, which will allow these products to be shipped to customers and used in procedures, effective immediately. The Company stated that the testing and process improvements for the remaining sizes of the AFX2 system are on-going. See our free and comprehensive research report on ELGX at:
On Monday, Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co.'s stock recorded a trading volume of 1.17 million shares, which was above its three months average volume of 1.14 million shares. Shares of the Company ended the session 0.58% higher at $168.87. The stock has gained 2.98% in the last one month and 2.01% on an YTD basis. The Company's shares are trading 0.55% and 0.50% above their 50-day and 200-day moving averages, respectively. Furthermore, shares of Becton, Dickinson, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 53.06.
On December 15th, 2016, Becton, Dickinson announced the launch of the BD Neopak™ 2.25 ml prefillable glass syringe, specifically designed for biopharmaceutical manufacturers that develop, manufacture and market high-value and sensitive biologic drugs that require higher quality levels and performance to treat chronic diseases such as, rheumatoid arthritis, psoriasis, lupus, and severe asthma.
On January 05th, 2017, research firm Raymond James downgraded the Company's stock rating from 'Strong Buy' to 'Outperform'. BDX free research report PDF is just a click away at:
Shares in Ewing, New Jersey headquartered Antares Pharma Inc. closed at $2.28, declining 0.87% from the last trading session. The stock recorded a trading volume of 756,511 shares, which was higher than its three months average volume of 720,500. The Company's shares have gained 11.76% in the last one month and 30.29% over the previous three months. The stock is trading 14.09% above its 50-day moving average and 66.77% above its 200-day moving average. Additionally, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 58.95.
On December 21st, 2016, Antares announced that it had submitted a New Drug Application to the US FDA for QuickShot® Testosterone (QST), a drug-device combination product for the delivery of testosterone enanthate using a subcutaneous auto injector. QST is intended to treat adult men with low testosterone associated with a condition known as hypogonadism. The Company stated that two hundred and eighty-three men participated in the QST phase-3 program. The phase-3 program consisted of a one year pivotal safety and efficacy study and a second 6-month safety study. Sign up for your complimentary report on ATRS at:
At the closing bell yesterday, shares in Morrisville, North Carolina headquartered TransEnterix Inc. ended 2.00% lower at $1.47 with a total trading volume of 679,382 shares. The stock has advanced 3.52% in the last one month and 13.08% since the start of this year. The Company's shares are trading slightly below their 50-day moving average by 0.96%. Furthermore, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have an RSI of 54.38.
On January 05th, 2017, TransEnterix announced that the Company has received an increased equity investment from SOFAR S.p.A valued at €5 million, or approximately $5.2 million. The investment was made pursuant to an amendment to the September 18th, 2015, agreement to purchase the Senhance technology and business operations from SOFAR. Including this investment, SOFAR owns approximately 16.1% of TransEnterix's outstanding common stock. Register for free on Stock-Callers.com and download the latest research report on TRXC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA